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Abstract
Circadian deficits in Huntington’s disease (HD) are recapitulated in both fragment (R6/2) and full-length (Q175) mouse models
of HD. Circadian rhythms are regulated by the suprachiasmatic nuclei (SCN) in the hypothalamus, which are primarily en-
trained by light detected by the retina. The SCN receives input from intrinsically photosensitive retinal ganglion cells
(ipRGCs) that express the photopigment melanopsin, but also receive input from rods and cones. In turn, ipRGCs mediate a
range of non-image forming responses to light including circadian entrainment and the pupillary light response (PLR).
Retinal degeneration/dysfunction has been described previously in R6/2 mice. We investigated, therefore, whether or not cir-
cadian disruption in HD mice is due to abnormalities in retinal photoreception. We measured the expression of melanopsin,
rhodopsin and cone opsin, as well as other retinal markers (tyrosine hydroxylase, calbindin, PKCa and Brna3), in R6/2 and
Q175 mice at different stages of disease. We also measured the PLR as a ‘readout’ for ipRGC function and a marker of light re-
ception by the retina. We found that the PLR was attenuated in both lines of HD mice. This was accompanied by a progressive
downregulation of cone opsin and melanopsin expression. We suggest that disease-related changes in photoreception by the
retina contribute to the progressive dysregulation of circadian rhythmicity and entrainment seen in HD mice. Colour vision is
abnormal in HD patients. Therefore, if retinal deficits similar to those seen in HD mice are confirmed in patients, specifically
designed light therapy may be an effective strategy to improve circadian dysfunction.
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Introduction
Huntington’s disease (HD) is an inherited neurodegenerative
disorder caused by an abnormal CAG expansion in the HD
gene (1). HD is characterised by progressive motor, cognitive
and psychiatric disturbances (2). Sleep disturbances and circa-
dian abnormalities are also common features of HD (3–7), and
are recapitulated in a number of different mouse models (8–12).
In mammals, the suprachiasmatic nuclei (SCN) of the hypo-
thalamus are the site of the master pacemaker regulating circa-
dian rhythms in physiology and behaviour (13,14). The light
detected by the retina is the primary cue for the entrainment of
the SCN oscillator to the environmental light/dark cycle (15).
Innervation of the SCN via the retinohypothalamic tract (16) is
primarily from melanopsin-expressing intrinsically photosensi-
tive retinal ganglion cells (ipRGCs). Furthermore, ipRGCs are
also involved in the regulation of other non-image forming re-
sponses to light, including the pupillary light response (PLR),
sleep induction and pineal melatonin release (17–19). Whilst
rods and cones are critically important for vision, they were ini-
tially thought not to be necessary for circadian photoentrain-
ment (20,21). However, mice lacking melanopsin can still
entrain to light/dark cycles, although they show deficits in
phase shifting and pupillary responses (19,22,23). By contrast,
mice lacking rods, cones and melanopsin no longer respond to
light (24). As such, rods and cones may also provide contribu-
tions to non-image forming responses under certain conditions
(22,25–27). These observations are explained by the fact that
ipRGCs also receive inputs from rods and cones. Selective
ablation of ipRGCs results in a loss of photoentrainment, show-
ing that these cells act as a conduit for light input to the SCN
(28).
Melanopsin ipRGCs have not been investigated in the retina
of either HD patients or mice. Given the prominent role of mela-
nopsin ipRGCs in mediating circadian photoentrainment, we in-
vestigated whether progressive neurodegeneration of ipRGCs,
loss of the rod or cone inputs, or loss of function of melanopsin
contribute to the progressive dysregulation of circadian rhyth-
micity and impairment of photic synchronization in HD. Such
loss may contribute to abnormal circadian entrainment pheno-
type (such as that seen in HD mice), whereas loss of all photore-
ception from the retina would result in free-running rather than
arrhythmia or rhythm fragmentation. For our studies, we used
a well characterised transgenic fragment HD mouse model (R6/
2 line) that shows a severe and rapid progression of disease
(3,29,30). We have shown previously that bright light therapy
has beneficial effects on behavioural deficits in R6/2 mice (31).
Bright light therapy may be effective in treating the circadian
disruption in R6/2 mice because the light input pathways be-
come impaired. We also used a ‘knock-in’ HD mouse (Q175),
that carries the HD mutation in a genetically-relevant context,
and recapitulates the HD circadian and sleep phenotype in a
slower fashion (9,10).
Neurodegeneration caused by mutant huntingtin first affects
neurons in the striatum and cerebral cortex (32), and then ex-
tends to all brain areas as the disease progresses (33).
Interestingly, mutant huntingtin protein aggregates (inclusions)
have been described in the retina of R6/2 mice as well as a related
R6/1 line (34,35). These inclusions were accompanied by retinal
degeneration and functional impairment in both lines of mice at
the end stage (34–37). We hypothesised that retinal deficits that
cause visual defects might also contribute to the dysregulation of
circadian rhythmicity. Unfortunately, the literature regarding HD
human retinal pathology is not only sparse but also conflicting. A
post mortem examination of the eyes of a single HD patient with
advanced disease did not reveal any histological abnormalities
(38). By contrast, cone function has been reported to be impaired
in patients performing visual tasks (39). Furthermore a recent
study revealed abnormalities in colour vision in HD patients who
had reduced thickness of the temporal part of the retinal nerve fi-
bre layer (RNFL), suggesting the involvement of the retina in the
neurodegenerative process of HD (40).
Our working hypothesis is that the deterioration of mela-
nopsin pathways in HD may play a role in the circadian disrup-
tion seen in HD patients. To address this, we measured the PLR
(that represents a readout for ipRGC functionality and a marker
of retinal sensitivity), and performed a detailed immunohisto-
chemical study of the HD retina. We assessed the expression of
key photopigments (melanopsin, ultraviolet sensitive (UVS) and
middle-wave sensitive (MWS) cone opsins and rhodopsin),
markers of other retinal cell types (tyrosine hydroxylase (TH),
calbindin, Brain-specific homeobox/POU domain protein 3a
(Brn3a) and protein kinase C alpha (PKCa)) and we examined
the occurrence of huntingtin (Htt) depositions (using MW8), in
retina from R6/2 and Q175 mice at different stages of the
disease.
Results
Pupil light responses are progressively affected in
R6/2 mice
In order to assess retina function and ipRGC output in wild type
(WT) and R6/2 mice, we stimulated one eye with a 10-s light
stimulus and recorded the PLR in the other eye, at 9, 12, 15, 18
and 20 weeks of age (Fig. 1). We tested five irradiances, ranging
from a bright light stimulus at 14.6 log quanta/cm2/s that in-
duced near complete consensual pupil constriction to a dim
light at 9.3 log quanta/cm2/s that induced almost no consensual
pupil response in normal WT mice. Irradiance response curves
were then constructed for WT and R6/2 mice at each age.
We observed an age-dependent decline in the PLR of R6/2
mice, but not in age-matched WT controls. We found a signifi-
cant effect of irradiance on the magnitude of pupil constriction
in WT and R6/2 mice at all ages [F(4,732)¼ 2103.28; P< 0.001;
Fig. 1A–E]. There were also significant age- and genotype-
related changes in PLR in interaction with irradiance across the
longitudinal study [light irradiance x age, F(4,732)¼ 36.21;
P< 0.001 and irradiance x genotype, F(16,732)¼ 3.24; P< 0.001]. At
9 weeks, there was already a significant effect of genotype on
PLR [F(1,37)¼ 6.73, P< 0.05; Fig. 1A], with presymptomatic R6/2
mice showing an attenuation of their response to light under
low irradiance at 11.6 log quanta/cm2/s compared to WT mice
(P< 0.01). At 12 weeks, there was an effect of genotype on PLR
[main effect: F(1,38)¼ 28.72, P< 0.001] as well as interaction be-
tween this factor and irradiances [F(4,152)¼ 6.46, P< 0.001;
Fig. 1B]. Post hoc analysis revealed that the attenuation in PLR
seen earlier at 11.6 log quanta/cm2/s compared to WT mice was
maintained at 12 weeks (P< 0.01). At this age, PLR deficits were
also seen at 10.5 and 12.9 log quanta/cm2/s (P< 0.01). At 15
weeks, the PLR deficits were maintained compared to age-
matched WT mice at 10.5, 11.6 and 12.9 log quanta/cm2/s
(Fig. 1C). Finally, while the R6/2 retina at late symptomatic
stages (18 and 20 weeks) was still able to constrict to 11.6 and
12.9 but not to 10.5 log quanta/cm2/s, the corresponding PLR re-
sponse was severely attenuated compared to WT mice (P< 0.01;
Figs. 1D and E; 2C, E, and G). Interestingly, the ability to achieve
maximal pupil constriction was only affected in the oldest R6/2
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mice tested (Fig. 1E), where R6/2 mice at 20 weeks showed a sig-
nificant attenuation in PLR under bright light condition at 14.6
log quanta/cm2/s (P< 0.05). As presented in Fig. 2I, the kinetic
profile of the PLR showed a slower initial phase of constriction
in R6/2 mice (maximal constriction at 11s) compared to WT
mice (6s). It is notable that almost half of 20 week old R6/2 mice
(8 out of 20) developed ptosis, characterised by the drooping of
the upper eyelid.
To verify whether or not there was an intrinsic defect in the
iris sphincter pupillae muscle of the R6/2 mice, a carbachol test
was performed (Fig. 1F). Both WT and R6/2 retinas were fully re-
sponsive to carbachol that induced full pupil constriction in all
mice. Thus, the muscles responsible for driving pupil constric-
tion were not affected, confirming that the changes in PLR seen
in R6/2 mice were not due to the inability of the pupil to
constrict.
Pupil light responses are attenuated in 20 month
old Q175 mice
To determine whether or not the PLR deficits seen in R6/2 mice
were recapitulated in a mouse model of HD with a slower
progression of disease, we tested Q175 mice at 9, 15 and 20
months of age using the same protocol (Fig. 3).
We observed a decline in PLR only in 20 month old Q175 ho-
mozygous (HOM) mice (Figs. 2D, F, H and J; 3C), while there was
no change in heterozygous (HET) and WT mice at any age
tested. We found, however, regardless of the age tested, an
overall effect of light irradiance [F(4,260)¼ 1174.86; P< 0.01] and
genotype [F(2,65)¼ 4.49; P< 0.05] on the magnitude of PLR in WT
and Q175 mice, as well as a significant interaction between
these factors [F(8,260)¼ 1.98; P< 0.05; Fig. 3]. Further analysis of
the data at 9 months or 15 months did not show any main ef-
fect of genotype in the PLR between Q175 HET, Q175 HOM or
WT mice [F(2,17)¼ 0.19; P> 0.05; (Fig. 3A) and F(2,24)¼ 0.36;
P> 0.05; (Fig. 3B), respectively]. At 20 months however, we
found a significant effect of genotype [F(2,24)¼ 9.36; P< 0.001],
light irradiance [F(4,96)¼ 423.20; P< 0.001] on the PLR, and also in
the interaction between these factors [F(8,96)¼ 2.35; P< 0.05; Fig.
3C]. Post hoc analysis revealed significant PLR deficits in HOM
mice at 11.6 and 12.9 log quanta/cm2/s compared to both WT
and HET mice. However, no differences were observed in re-
sponse to bright light stimuli, with levels of pupil constriction
similar between HOM and WT mice at 14.6 log quanta/cm2/s.
Figure 1. Progressive deficits in pupillary responses to light in R6/2 mice. A single light exposure (10 s, 470 nm) was tested at five different irradiances (9.3, 10.5, 11.7,
12.9 and 14.6 log quanta/cm2/s) to test consensual pupillary responses. (A–E) Phase response curves to light irradiance are shown from wild type (WT, black symbols
and solid line) and R6/2 (white symbols and dashed line) mice at 9, 12, 15, 18 and 20 weeks. (F) Representative images of pupil size from R6/2 and WT mice at 20 weeks,
recorded before the light stimulus in total darkness (dark) and at maximal constriction in response to a 10-s light exposure at 9.3, 10.5, 11.7, 12.9 and 14.6 log quanta/
cm2/s, and 10 min after application of carbachol (Carb). Data shown in A-E are the mean maximal pupil constriction observed following light exposure from 19 to 20
mice6SEM. Curves are fitted to a sigmoid function. Where error bars are not visible, they are obscured by the symbols. *P< 0.05, **P<0.01.
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No differences were found between HET and WT mice. The ki-
netic profile of the PLR presented in Fig. 2J shows an initial
phase of constriction similar between HOM and age-matched
WT mice (with maximal pupil constriction reached at 8.4 and
7.4s, respectively), but HOM mice had a slightly more rapid re-
covery of pupil size compared to WT mice. It is notable that
half of the 20 month old Q175 HOM mice (4 out of 8) developed
ptosis.
Figure 2. Dynamics of pupil light reflex in R6/2 and homozygous Q175 mice at late stage of lifespan. Consensual pupil constriction profiles shown are recorded from 20
week old R6/2 (A,C,E,G,I) and 20 month old Q175 homozygous (HOM) (B,D,F,H,J) mice in response to 10-s light exposure at different illumination irradiance: 9.3 (A, B),
10.5 (C, D), 11.7 (E, F), 12.9 (G, H) and 14.6 (I, J) log quanta/cm2/s. The bar above the traces indicate the duration of light stimuli (from 2 to 12 s). All data are mean of
response6SEM.
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As with WT mice, Q175 HET and Q175 HOM pupils fully con-
stricted in response to carbachol confirming that the muscles
responsible of the pupil constriction were not affected (Fig. 3D).
Overall, the PLR phenotype was similar between R6/2 and
Q175 mice. For both models, attenuated PLR was observed at
low and moderate intensities of light, with full pupil constric-
tion observed to bright light stimuli at all-time points, with the
exception of the oldest R6/2 mice tested. This phenotype is in-
consistent with a deficit in melanopsin alone, as the PLR pheno-
type of melanopsin-deficient (Opn4-/-) mice is characterised by a
failure to reach full constriction to bright light stimuli with nor-
mal constriction observed at moderate and low intensities of
light. The PLR phenotype observed in R6/2 and Q175 mice is
therefore likely to be caused, at least in part, by a functional
change in rod- and cone-driven signals, or potentially other
structural changes in the PLR machinery. Changes in the on-
set kinetics of PLR responses would also indicate a change in
rod- and cone-driven signals, as the sluggish responses of
melanopsin make it unlikely that this photopigment contrib-
utes to the initial rapid phase of pupil constriction.
Immunostaining of rods, cones and melanopsin in
R6/2 retina
To determine the basis of the PLR phenotype observed in R6/2
and Q175 mice, we used immunostaining to perform a detailed
analysis of the retina of these mice, focusing primarily on the
number and distribution of rods, cones and melanopsin-
expressing ganglion cells. Initial examination of 20 week old
R6/2 retina (n¼ 6 R6/2 and n¼ 6 WT) showed a number of clear
abnormalities compared to WT littermate controls (Fig. 4A and
B). 20 week old R6/2 mice showed an extensive degree of retinal
dysplasia, with the outer layers of the retina clearly invaginat-
ing into the inner layers (Fig. 4A). These anatomical changes
were accompanied by a complete loss of cone opsin staining
across the retina (Fig. 4A), and a widespread downregulation of
melanopsin expression which was observed for all subtypes of
ipRGCs (Fig. 4B). Loss of cone opsin expression was also accom-
panied by signs of cone degeneration in the few remaining
cones identified, such as loss of outer segments and misloca-
lisation of opsin to the cell body. There was no indication of a
widespread loss of rod photoreceptors in 20 week old R6/2 ret-
ina, although there are signs of rhodopsin protein misloca-
lisation (an early sign of rod degeneration), with rhodopsin
staining now also evident around the cell bodies located within
the outer nuclear layer (Fig. 4A).
Consistent with previous reports (41), a dorsal ventral gradient
in melanopsin expression was observed in the retina from WT
mice (Fig. 4B; Supplementary Material, Fig. S1A). A similar pat-
terning of melanopsin expression was also evident in 20 week old
R6/2 mice retina, although there was a clear and consistent re-
duction in levels of melanopsin staining observed across the ret-
ina compared to that seen in WT controls (Fig. 4B; Supplementary
Material, Fig. S1B). Levels of Brn3a staining, and the total numbers
of retinal ganglion cells (RGCs) were not obviously different be-
tween 20 week old R6/2 retina and WT controls (Fig. 4A and B).
Figure 3. Defects in pupillary responses to light in 20 month old homozygous Q175 mice. A single light exposure (10 s, 470 nm) was tested at five different irradiances
(9.3, 10.5, 11.7, 12.9 and 14.6 log quanta/cm2/s) to induce consensual pupillary constriction. (A-C) Phase response curves to light irradiance are shown from wild type
(WT, black symbols and solid line), Q175 heterozygous (HET, grey symbols and dashed line) and Q175 homozygous (HOM, white symbols and dotted line) mice at 9, 15
and 20 months. (D) Representative images of pupil area from Q175 and WT mice at 20 months, recorded in dark and at maximal constriction in response to a 10-s light
exposure at 9.3, 10.5, 11.7, 12.9 and 14.6 log quanta/cm2/s, and 10 min after application of carbachol (Carb). All data in A-C are mean maximal pupil constriction ob-
served following light exposure from 6 to 12 mice6SEM. Curves are fitted to a sigmoid function. Where error bars are not visible, they are obscured by the symbols.
Asterisks show significant difference between Q175 HOM and WT mice, **P<0.01. Hashes show significant differences between Q175 HOM and HET mice, #P<0.05 and
##P<0.01. There were no statistical differences between response of Q175 HET and WT mice.
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Following the initial observations from retina of 20 week old
R6/2 mice, we next used immunocytochemistry and quantita-
tive polymerase chain reaction (qPCR) analysis to examine the
progression of the retina phenotype in R6/2 and WT mice aged 9
weeks, 12 weeks, 15 weeks and again 20 weeks (n¼ 4 for ICC,
n¼ 5 for qPCR) (Fig. 5; Supplementary Materials, Figs. S1–S5).
Additionally, we examined retina from Q175 mice (HOM, HET
and WT littermates) at 20 months (n¼ 3 for ICC, n¼ 5 for qPCR)
(Fig. 7; Supplementary Materials, Figs. S7–S9). Downregulation
of cone opsin and melanopsin expression was evident in both
R6/2 and Q175 mice.
Levels of UVS cone opsin expression were normal in R6/2
mice at 9 weeks of age, but rapidly declined by 12 weeks, with a
complete loss of UVS opsin staining evident by 15 weeks
(Fig. 5A; Supplementary Materials, Figs. S2B and S5D). A similar
timeline was observed for the downregulation of both UVS and
MWS cone opsins (Supplementary Material, Fig. S3), and also
UVS opsin mRNA (Supplementary Material, Fig. S5A). By com-
parison, WT mice showed no significant changes in levels of
cone opsin staining at any time point investigated (Fig. 5A), and
cone opsin staining was entirely consistent with previous re-
ports of dorsal ventral gradients of both UVS and MWS cone op-
sin expression in the mouse retina (41,42; Supplementary
Material, Figs. S2 and S3).
Examination of UVS opsin staining in R6/2 mice at 12 weeks in-
dicated not only a downregulation of cone opsin expression but
also signs of cone degeneration, indicated by both morphological
changes and mislocalization of cone opsin to cell bodies. To con-
firm that changes in opsin expression reflect cone degeneration,
we also studied the expression of cone arrestin and performed la-
belling with peanut agglutinin (PNA) lectin that specifically labels
cone cell membranes (Supplementary Material, Fig. S4).
Expression of cone arrestin is downregulated by 9 weeks of age in
the R6/2 retina compared to WT controls and is completely absent
by 12 weeks, preceding the loss of cone opsin expression
(Supplementary Material, Fig. S4A). By contrast PNA labelling of
cone cell membranes was evident in R6/2 mice at 15 weeks in the
absence of UVS opsin staining, indicating that loss of cone opsin
and cone arrestin expression occurs prior to cone degeneration
(Supplementary Material, Fig. S4B). Widespread disruption of PNA
labelling and degeneration of cone cell bodies was not observed in
R6/2 mice until 20 weeks of age (Supplementary Material, Fig. S4B).
In keeping with our initial findings, we observed a time-
dependent decrease in melanopsin expression in R6/2 mice
(Fig. 5B; Supplementary Materials, Figs. S1 and S5). Melanopsin
expression levels were downregulated by 12 weeks of age, and
reduced further with age. At 15 week and 20 week time points,
melanopsin staining was markedly reduced, and close to levels
of background staining (Fig. 5B; Supplementary Material, Fig.
S1). In contrast to the clear evidence of degeneration observed
for cone photoreceptors, however, there were no obvious signs
of ipRGC degeneration in R6/2 mice. By increasing laser power
and levels of signal gain during confocal image acquisition, it
was possible to observe melanopsin expressing cells within
aged R6/2 retina. In all cases where melanopsin could be visual-
ised, the anatomy and morphology of ipRGCs appeared normal
in R6/2 retina up to 15–20 weeks, albeit with markedly lower lev-
els of melanopsin expression than was seen in WT controls.
Levels of melanopsin expression remained similar in WT mice
at all ages tested (Fig. 5B; Supplementary Material, Fig. S1), with
the number and distribution of ipRGCs consistent with previous
studies using similar approaches (41). Consistent with these ob-
servations, qPCR analysis showed a downregulation of mela-
nopsin mRNA in R6/2 mice over time, although this effect was
less dramatic than the reduction in melanopsin immunostain-
ing (Supplementary Material, Fig. S5B and E).
To determine if Htt aggregates occur in ipRGCs, double
immunostaining of aggregated Htt and melanopsin was per-
formed. Levels of aggregated Htt detected in R6/2 retina show a
steady increase over time, with high levels of aggregated Htt de-
tected in all retinal layers at 20 weeks (Supplementary Material,
Fig. S6A). Interestingly, Htt labelling was found to be almost
completely absent from ipRGCs in R6/2 mice at 15 weeks, de-
spite the presence of Htt aggregates within the vast majority of
cells in the ganglion cell layer (and other retinal layers) at this
time point. Aggregated Htt was, however, routinely detected
Figure 4. Downregulation of cone opsin and melanopsin expression in R6/2 retina at late stage of disease. Images collected from the dorsal and ventral regions of retina
from 20 week old WT (A, left panels; B, left panels) and R6/2 (A, right panels; B, right panels) mice following labelling with anti-rhodopsin (red) and anti-UVS cone opsin
(green) to label rods and cones (A) and anti-melanopsin (red) and anti-Brn3a (green) to label ipRGCs and RGCs (B). DAPI nuclear counterstain is shown in blue. ONL,
outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer.
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within ipRGCs of R6/2 mice at 20 weeks (Supplementary
Material, Fig. S6B).
By comparison with cones and ipRGCs, rod photoreceptors
and levels of rhodopsin staining appeared normal in R6/2 mice at
time points far beyond those at which downregulation of cone
opsin and melanopsin expression was observed (Fig. 6A). Levels
of rhodopsin staining were similar to WT controls up to 15 weeks.
Signs of rod degeneration were, however, evident in R6/2 mice at
20 weeks, although this is likely to be secondary to the significant
anatomical remodelling of the retina layers that occurs by this
time point (only minimal levels of retinal dysplasia were ob-
served prior to 15 weeks of age). Similarly, levels and patterning
of calbindin staining (labels horizontal cells and a subset of ama-
crine cells; Fig. 6A) and PKCa staining (labels ON bipolar cells; Fig.
6B) appeared normal in R6/2 mice at all time points, with a dis-
ruption in the patterning of staining only evident at 20 weeks due
to extensive retina dysplasia. Whilst there was a slight reduction
in levels of tyrosine hydroxylase (TH) mRNA (Supplementary
Material, Fig. S5C), there was no difference in levels of TH staining
detected within dopaminergic amacrine cells of the R6/2 retina
(Fig. 6B, Supplementary Material, Fig. S5F). The levels of Brn3a ex-
pression, and the total number of RGCs also appeared normal be-
tween R6/2 and WT mice at all time points (Fig. 6C).
Immunostaining of rods, cones and melanopsin in
Q175 mice
As seen in R6/2 mice, a complete loss of UVS opsin, MWS opsin
and cone arrestin expression was evident in the retina of Q175
HOM mice at 20 months (Fig. 7A; Supplementary Material, Fig.
S7A and B), with widespread cone degeneration observed in
Q175 HOM mice at this time point as evident by a loss of PNA la-
belling (Supplementary Material, Fig. S8). Q175 HOM mice also
showed a downregulation of melanopsin expression, although
this effect was less obvious than that observed for R6/2 mice
(Fig. 7B, Supplementary Material, Fig. S9). Interestingly, Q175
HET mice showed an intermediate phenotype, with an incom-
plete loss of UVS opsin and cone arrestin staining evident in
these mice at similar ages (Fig. 7A; Supplementary Material, Fig.
S7A and B), and only a subtle reduction in levels of melanopsin
Figure 5. Time course of cone opsin and melanopsin expression in R6/2 mice. (A) Images showing the levels of UVS cone opsin observed in flatmount retina from WT
and R6/2 mice at 9, 12, 15 and 20 week of age. All images collected from the ventral retina where all cones express UVS opsin. (B) Images showing the levels of melanop-
sin observed in flatmount retina from WT and R6/2 mice at 9, 12, 15 and 20 weeks of age. All images collected from the ventral retina. The levels of UVS cone opsin and
melanopsin observed in the dorsal and ventral retina, as well as the expression of UVS and MWS cone opsin, is shown in Supplementary Materials, Figs S1, 2 and 4).
Quantification of UVS opsin and melanopsin immunofluorescence and qPCR analysis of UVS opsin and melanopsin mRNA expression in R6/2 mice are shown in
Supplementary Material, Fig. S9.
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expression (Fig. 7B; Supplementary Material, Fig. S9). There
were also clear examples of dysplasia in retina from 20 month
old Q175 HOM mice but not in Q175 HET mice, although this
was less severe than that seen in R6/2 mice (for example see
Supplementary Material, Fig. S7C). Rhodopsin staining was
normal in Q175 HET and Q175 HOM mice (Fig. 7C), as were levels
of calbindin (horizontal cells and amacrine cells) (Fig. 7C), PKCa
(ON bipolar cells) (Supplementary Material, Fig. S7C) and Brn3a
labelling (RGCs) (Supplementary Material, Fig. S7D). There was
no difference in levels of TH staining detected within
Figure 6. Rods, ON bipolar cells, horizontal cells, amacrine cells and retinal ganglion cells are unaffected in R6/2 mice. (A) Images showing labelling of anti-rhodopsin
(green, labels rods) and anti-calbindin (red, labels horizontal cells and a subset of amacrine cells) in WT and R6/2 retina at 9, 12, 15 and 20 weeks of age. (B) Images
showing labelling of anti-protein kinase-C alpha (PKCa) (red, labels ON bipolar cells) and anti-tyrosine hydroxylase (TH) (green, labels dopaminergic amacrine cells) in
WT and R6/2 retina. (C) Images showing labelling of anti-Brn3a (green, marker of retinal ganglion cells) in WT and R6/2 retina. DAPI nuclear counterstain is shown in
blue. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer.
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dopaminergic amacrine cells of Q175 HOM retina (Fig. 7D;
Supplementary Material, Fig. S9), although similarly to R6/2
mice, a subtle reduction in levels of TH mRNA were detected in
Q175 HOM mice (Supplementary Material, Fig. S9).
Discussion
HD mouse models recapitulate the circadian abnormalities seen
in patients. In this study, we found that both R6/2 and Q175
mice had a progressive attenuation of the PLR (that we used as
a marker of ipRGC activity), accompanied by a range of morpho-
logical abnormalities in the retina. These included a downregu-
lation of melanopsin and cone opsin expression, and ultimately
degeneration of cones but not of ipRGCs. Since ipRGCs play a
primary role in mediating both the PLR and circadian photoen-
trainment, the retinal deficits found in R6/2 and Q175 HD mice
may contribute to the circadian breakdown seen in HD.
R6/2 mice show a rapid progression of disease, with circa-
dian abnormalities appearing from the age of 10–12 weeks and
resulting in a complete disintegration of rest-activity rhythms
Figure 7. Downregulation of cone opsin and melanopsin expression in Q175 retina at late stage of disease. (A) Images showing the levels of UVS cone opsin observed in
flatmount retina from WT, Q175 heterozygous (HET) and Q175 homozygous (HOM) mice at 20 months of age. All images collected from the ventral retina where all
cones express UVS opsin. (B) Images showing the levels of melanopsin observed in flatmount retina from WT, Q175 HET and Q175 HOM mice at 20 months of age. All
images collected from the ventral retina. (C) Images showing levels of anti-rhodopsin (green, labels rods) and anti-calbindin labelling (red, labels horizontal cells and a
subset of amacrine cells). (D) Images showing levels of anti-tyrosine hydroxylase labelling (green, marker of dopaminergic amacrine cells) observed in flatmount retina
from WT, Q175 HET and Q175 HOM mice at 20 months of age. DAPI nuclear counterstain is shown in blue. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, gan-
glion cell layer. Images showing the levels of anti-UVS cone opsin, anti-MWS opsin, anti-protein kinase-C alpha (PKCa), and anti-Brn3a labelling are shown in
Supplementary Material, Fig. S7. Loss of PNA labelling in Q175 HOM mice at 20 months is shown in Supplementary Material, Fig. S8.
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by 15–16 weeks and an early death at 24 weeks (43). The PLR
deficit was mild at 9 weeks (presymptomatic stage), and wors-
ened by 12 weeks, the age at which the R6/2 mice start to be-
come arrhythmic. PLR deficits were seen in the Q175 HOM mice
by the age of 20 months, at which time abnormalities but not
complete breakdown of rest-activity rhythms are also seen
(44). By contrast, 20 month old Q175 HET mice still had no ap-
parent deficits in their PLR compared to the age-matched WT
mice, an age at which they do not show major circadian
abnormalities.
Both melanopsin, and rod/cone-based signals contribute to
driving the PLR. Transgenic mice without functioning rods and
cones and lacking melanopsin, lose the ability to constrict their
pupil in response to light (24). By contrast, mice lacking both
rods and cones but with a functional melanopsin system still
maintain the PLR, albeit with a reduced sensitivity (45). Mice
lacking only melanopsin show a PLR similar to WT mice at dim
light irradiance, but incomplete PLR at high irradiance, failing to
reach full pupil constriction to bright light (19). In R6/2 mice, we
observed attenuated PLR at low and moderate irradiances at 12
and 15 weeks (an indication of rod/cone deficits), and a failure
to reach full pupil constriction observed in 20 week old R6/2
mice. These data suggest that at 20 weeks of age, the phenotype
of R6/2 mice is similar to that seen in melanopsin knockout
mice, with a failure to reach full constriction in response to
bright light (19).
With respect to circadian defects, the loss of either rods,
cones or melanopsin would be expected to result in only subtle
circadian phenotypes, as these different photoreceptors per-
form overlapping roles in providing light input for non-image
forming responses (46–48). As ipRGCs provide the principal
conduit for rod- and cone-driven inputs to the SCN, downregu-
lation of melanopsin does not preclude rods and cones driving
non-image forming responses to light. Our analysis of the HD
retina revealed a range of morphological abnormalities in the
retina of R6/2 mice, with the earliest pathology observed being
the loss of proteins necessary for normal cone function, includ-
ing cone opsins and cone arrestin (necessary for termination of
cone light responses). We observed a reduction of rhodopsin
expression and disruption of rod photoreceptors only at the
latest age points, with these changes only evident following
the onset of retina dysplasia. Previous studies have suggested
that the dark adapted PLR is primarily dependent upon an in-
teraction between cones and melanopsin, with cones mediat-
ing responses at lower irradiances and melanopsin primarily
contributing at higher irradiances (25). Our data are consistent
with this model, with PLR defects at low irradiances explained
by the marked degeneration of cone opsin, whereas melanop-
sin defects become apparent at higher irradiances in older
mice. Previous studies have shown that classical photorecep-
tors play a role in regulating melanopsin expression (49–51). As
such, the loss of cone function could plausibly account for the
changes in melanopsin expression observed. However, aging
studies on mice lacking all rods and cones (rd/rd cl) show no
changes in melanopsin mRNA or levels of immunostaining us-
ing the same methods used in this study (52). As such, the dra-
matic changes we describe here appear unlikely to be due to
the loss of cone function alone.
In agreement with a previous study (34), we did not find any
changes in the number and morphology of retinal ganglion cells
in symptomatic R6/2 mice. We did, however, observe a progres-
sive downregulation of melanopsin expression within ipRGCs of
R6/2 retina, including all ipRGC subtypes that are detectable by
immunostaining (41).
At 20 weeks of age (end stage), R6/2 mice showed a severe
downregulation of melanopsin. This is consistent with the di-
minished PLR at high irradiance as described above (19). Despite
the downregulation of melanopsin expression, there were no
observable changes in the morphology of ipRGCs, or evidence of
neurodegenerative loss of ipRGCs at any stage of disease stud-
ied in R6/2 mice. Moreover, despite the widespread accumula-
tion of Htt aggregates in the retinal ganglion cell layer by 15
weeks of age, ipRGCs contained few, if any, detectable aggre-
gates at this time point. However, aggregates were commonly
detected within ipRGCs at 20 weeks, corresponding to the age at
which impaired maximum pupil constriction is evident in R6/2
mice. The preservation of ipRGCs could be explained by a spe-
cific resistance to neurodegeneration caused by alterations in
mitochondrial function (53,54), which play major roles in the
pathogenic processes in HD (55).
The loss of cones and reduction in melanopsin expression
observed in R6/2 mice was recapitulated in Q175 mice. The com-
bined downregulation of cone opsin and also melanopsin ex-
pression represents a ‘double hit’ loss-of-function, and may
combine to contribute to phenotypes observed in R6/2 and Q175
mice. However, the progression and severity of PLR phenotypes
observed in R6/2 and Q175 mice may potentially be explained
better by the timeline of melanopsin downregulation in these
mouse models than by the loss of cone opsin. Loss of cone opsin
is complete in both mouse models, yet Q175 mice have a more
subtle phenotype consistent with the more subtle loss in levels
of melanopsin expression.
Together, our results suggest that retinal degeneration, and
in particular the marked deterioration of cone and melanopsin
pathways in HD mice likely result in reduced retinal photore-
ception and changes in levels and properties of light informa-
tion transmitted from the retina. These changes may contribute
to the progressive dysregulation of circadian rhythmicity seen
in HD. As the disease progresses, the circadian system of R6/2
and aged Q175 HOM mice becomes increasingly insensitive to
the external light-dark (LD) cycle, particularly when the envi-
ronmental light levels are low. Consistent with these defects in
light input, bright light therapy was able to reverse the rest-
activity rhythm dysfunction in R6/2 mice (31).
Dopamine is present in the retina, produced by a subclass
of amacrine cells where it is involved in neural processes for
light adaptation (56). Since there is evidence to suggest that
melanopsin expression and levels of dopamine are interde-
pendent in the retina (57–59), it was tempting to suggest that
an imbalance of the retinal dopaminergic system causes the
downregulation of melanopsin expression. For both R6/2 and
Q175 mice, however, we found that dopaminergic amacrine
cells and levels of TH expression were unaffected by disease
progression, although subtle reductions in levels of TH mRNA
expression were observed for both R6/2 and Q175 mice. Further
investigations are needed to understand why melanopsin ex-
pression is specifically and progressively reduced in R6/2 and
Q175 mice.
Some studies have reported abnormal cone function and col-
our vision in HD patients (39,40), suggesting the involvement of
the retina in the process of HD degeneration. To our knowledge,
however, none has reported a link between retinal dysfunction
and circadian abnormalities. In other neurodegenerative dis-
ease such as Parkinson’s disease (PD) and Alzheimer’s disease
(AD), there is evidence for a contribution of retinal deficits to cir-
cadian abnormalities (60–62). For example in AD, a post mortem
study of retina revealed a specific pathology and loss of ipRGCs
associated with b-amyloid deposits (61), suggesting that ipRGC
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degeneration contributes to circadian dysfunction (62).
Therefore, the retina may be a tissue of interest in HD to assess
not only the role of melanopsin expression and circadian photo-
reception in the pathogenesis of circadian abnormalities but
also the possibility of using circadian photoreception as a
marker of disease progression.
Finally, a bright light therapy has beneficial effects for pa-
tients with AD (63) and PD (64) but to date this has not been in-
vestigated in HD patients. Given that bright light therapy
effectively delays the deterioration of circadian rhythms in HD
mice (31), this might be a promising non-pharmaceutical strat-




Experiments were conducted under the UK Animals (Scientific
Procedures) Act 1986 with the approval of the University of
Cambridge License Review Panel. R6/2 Q250 (10 males and 10 fe-
males) and WT (10 males and 10 females) mice were taken from
a colony established in the University of Cambridge (CBA x
C57Bl/6J background). WT (18 males and 2 females) and Q175
mice (28 males and 28 females) on a C57Bl/6J background were
obtained from a colony established in the University of
Cambridge, which originated from founders obtained from the
Jackson Laboratory (Bar Harbor, Maine, USA). Genotyping and
determination of the CAG repeat length were carried out on tail
biopsies by Laragen (Los Angeles, USA) using GeneMapper. R6/2
Q250 males had a mean of CAG repeat length of 24961 and fe-
males 24861. Q175 HET for the mutation (n¼ 35) had a mean
CAG repeat length of 16661 and HOM for the mutation (n¼ 25)
had a mean CAG repeat length of 15961 for the shorter allele
and 17361 for the long allele.
Husbandry
Prior to the experiments, mice were kept in age-matched groups
of up to 10 animals of the same sex and genotype for R6/2 mice
and of the same sex and mixed genotype for Q175 mice. Mice
were kept in a controlled environment with 12:12 LD cycle, at a
room temperature of 21–23 C and humidity of 55%6 10. Mice
had free access to dry laboratory food and water in lowered bot-
tles with elongated spouts. The mice were transferred to clean
cages twice weekly.
Pupillometry
The pupil light reflex is the physiological response that regu-
lates the amount of light reaching the retina by changing the
pupil diameter. Prior to the pupil light reflex test, mice were
dark adapted in constant darkness in a ventilated circadian cab-
inet (Scanbur, Denmark) for at least 1 h. The pupillometry test-
ing was conducted in the light period of a 12:12 LD cycle
between ZT4 and ZT8 (4–8 h after the lights onset).
R6/2 and Q175 mice were tested at different stages of the dis-
ease. A group of R6/2 mice (10 males and 10 females for each
group) was tested longitudinally at 5 different ages that repre-
sented different stages of disease; a presymptomatic stage
(9 weeks), early symptomatic stage (12 and 15 weeks) and late
stage of the disease (18 and 20 weeks) to study progressive
phenotype.
Q175 mice were tested cross-sectionally. Q175 mice (n¼ 76)
were distributed into 3 experimental groups by age and tested
at 9 months (presymptomatic; 6 WT, 8 HET and 6 HOM mice), 15
months (early symptomatic; 7 WT, 12 HET and 9 HOM mice) and
20 months (symptomatic; 7 WT, 12 HET and 9 HOM mice).
Monochromatic light (470 nm) delivered by a LED light
source (Luxeon Rebel LED assembly, SR-01-B0040) was used to
stimulate one eye, and pupillary light responses under bright
light (14.6 log quanta/cm2/s) were measured from the other eye.
Lower irradiances (12.9, 11.6, 10.5 and 9.3 log quanta/cm2/s)
were tested by positioning corresponding neutral density filters
into the light path. The irradiances were measured and verified
with a radially calibrated spectrophotometer (Ocean Optics,
UK). Using routine laboratory handling techniques as previously
described (65), the mice were ‘scruffed’ and placed onto a plat-
form. The mice were positioned so that one eye received the
LED light and the pupil response in the contralateral eye was re-
corded by an IR-sensitive CCD camera (Prosilica, GC1020). The
camera was connected to a PC computer with custom-made
pupillometry software (Pupil6.3.vi running in LabView) which
set up the recording of the consensual pupil response to the
light stimulus by 5 frames per second, and controlled the dura-
tion of the light delivery as follows: 2 s in dark (pre-stimulus),
10 s of light (stimulus) followed by 17 s of dark (post-stimulus,
recovery). The pupil images were collected by the software con-
trolling stimulus presentation. The images were analysed with
ImageJ (http://rsbweb.nih.gov/ij/), allowing pupil area measure-
ment for each image. In some cases, the pupil was not entirely
visible (due to whiskers cutting the pupil area or ptosis in symp-
tomatic HD mice); this prevented the use of the automatic anal-
ysis. For these cases, pupil diameter was manually analysed
using ImageJ. The responsive pupil areas or diameter were cal-
culated as a percentage of the baseline pupil area or diameter
(when fully dilated under dark).
Only results from animals for which we had full data for the
five irradiances tested are presented. For R6/2 mice, data
shown at 9 weeks are from 19 R6/2 and 20 WT mice; at 12 weeks
from 20 R6/2 and 20 WT mice; at 15 weeks from 16 R6/2 and
20 WT mice; at 18 weeks from 20 R6/2 and 19 WT mice, and at
20 weeks, from 19 R6/2 and 19 WT mice. For Q175 mice, data
shown at 9 months are from 6 WT, 8 HET and 6 HOM mice; at
15 months from 6 WT, 12 HET and 9 HOM mice; and at 20
months from 7 WT, 12 HET and 8 HOM mice. Data from male
and female R6/2 mice were originally analysed separately. We
found that while the magnitude of PLR deficit was slightly
greater in females than in R6/2 males (compared to control
sex-matched mice), the PLR deficits had the same trends. We
therefore pooled the data from both sexes for clarity of
presentation.
Drugs
At 5 to 10 min prior to PLR testing, mice received a topical appli-
cation of tropicamide 1% (Sigma) to prevent constriction in the
stimulated eye (45). Consensual pupil constriction was mea-
sured in the contralateral (undilated) eye. Carbachol (carbamyl-
choline chloride, Sigma) was prepared at the concentration of
100 mM in 1X phosphate-buffered saline (PBS). Carbachol indu-
ces pupil constriction in normal mice and was tested in R6/2
and Q175 mice as a control to verify whether or not the animals
have an intrinsic defect in the iris sphincter pupillae muscles
that are responsible for pupil constriction (45). The drug was ap-
plied topically to the cornea of the mouse eye with a microtip
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transfer pipette and the pupil response was assessed in dark-
ness, before, and 10 min after drug application.
Immunocytochemistry
Four groups of R6/2 and age-matched WT mice were killed at 9,
12, 15 and 20 weeks (n¼ 7–8); Q175 mice and WT littermates
(n¼ 6 for each genotype) were killed at 20 months. All the mice
were killed at the same time of day, between ZT7 and ZT8, in or-
der to match the time window at which PLR tests were per-
formed (ZT4-ZT8). Preparation and immunostaining of retina
sections and whole retina flatmounts was performed as de-
scribed previously (41,66). We used primary antibodies against
melanopsin (as a marker of ipRGCs), UVS and MWS cone opsins
(as markers of cones), rhodopsin (as a marker of rods), TH (as a
marker of dopaminergic amacrine cells), PKCa (as a marker of
ON bipolar cells), calbindin (as a marker of horizontal cells and
a subset of amacrine cells), Brn3a (as a marker of retinal gan-
glion cells immunonegative for melanopsin), cone arrestin (a
marker of cones), and MW8 (as a marker of Htt aggregates).
Primary antibodies were incubated for 24 h (sections) or 72 h
(retina flatmounts) at 4

C, PNA lectin (specifically labels cone
cell membranes) conjugated to Alexa-568 (Thermo Fisher) was
incubated at 50 mg/ml for 2 h at room temperature. For staining
with the MW8 antibody, in an attempt to reduce ‘mouse on
mouse’ background staining, sections were first incubated with
unconjugated donkey anti-mouse monovalent Fab fragments
(Jackson Immunoresearch) 1:100 for 2 h at RT to block endoge-
nous IgGs present in the mouse tissue. Secondary antibodies
were incubated at 1:200 for 2 h at room temperature (sections)
or 24 h at 4

C (flatmounts). All secondary antibodies were raised
in donkey and conjugated with Alexa dyes (Thermo Fisher). A
summary of the different antibodies and dilutions used are
shown in Table 1. For retinal sections, all antibodies were di-
luted in PBS with 2.5% donkey serum and 0.2% Triton-X. All
wash steps were performed using PBS with 0.05% Tween-20. For
staining of retina flatmounts, levels of Triton-X were increased
to 1%. Samples were mounted in Prolong Gold anti-fade media
containing DAPI (Thermo Fisher).
Quantification of immunofluorescence
Quantification of immunofluorescence levels in confocal images
collected from whole retina flatmounts was performed using
ImageJ software (NIH; rsbweb.nih.gov/ij/). In order to ensure all
images were processed under identical conditions all individual
images for comparison were first compiled into an image stack.
Background subtraction and then threshold analysis were
performed on all images within the stack using automated set-
tings within ImageJ. For analysis of cone opsin staining the per-
centage area of each image deemed above threshold was
calculated to provide a measure of the retina area covered by
UVS opsin. Due to the lower density of ipRGCs and TH positive
amacrine cells, the mean greyscale values of each image area
above threshold were calculated and used as a quantitative
measure of intensity of immunofluorescence signal. All mea-
surements were performed using default settings in ImageJ.
Images were collected from n¼ 3–4 retina per group, with multi-
ple images collected from each retina averaged to produce a sin-
gle value per retina. Images used for quantification were
typically acquired at low magnification (x20 objective) to maxi-
mise the area of the retina used for analysis. All images were
collected from the ventral retina. Data are shown normalised to
values calculated for WT retina at 9 weeks.
qPCR
Following enucleation, whole eyes were stored at 80C prior to
use. Tissue was homogenised in TRIzol Reagent (Thermo
Fisher) and total RNA isolated using RNeasy spin columns
(Qiagen) with on column DNase treatment (Qiagen). 1mg of total
RNA was reverse transcribed using SuperScript III with
oligo(dT)20 primers (Thermo Fisher) and qPCR performed using
Quantifast SYBR Green PCR mastermix (Qiagen) on a StepOne
thermal cycler (Applied Biosystems). Quantification of
transcript levels was performed using a comparative threshold
cycle approach (67) with levels of target gene expression
normalised to the geometric mean expression of three house-
keeping genes (Arp, Tbp and Gapdh). Primer sequences were as
follows; UVS F; TCTTCACAGTCTTCATCGCCAGC; UVS R;
TTCAAAAGCCAGGAAAGCCAATG; Opn4 F; TCACAGGGAT
GCTGGGCAATC; Opn4 R; TTCTTGTAGAGGCTGCTGGCAAAG;
Thy-1F; TGCTGTTCTCAACCTGCTCTTCTCC; Thy-1R, GGGTCTC
TAAGTGGTGGATTTTGGC; Arp F; CGACCTGGAAGTCCAACTAC;
Arp R; ATCTGCTGCATCTGCTTG; Tbp F; TGGGCTTCCCA
GCTAAGTTC; Tbp R; GGAAATAATTCTGGCTCATAGCTACTG;
Gapdh F; TGCACCACCAACTGCTTAG; Gapdh R; GATGCAGGGAT
GATGTTC.
Image acquisition
Fluorescent images were collected using an LSM 710 laser scan-
ning confocal microscope and Zen 2009 image acquisition soft-
ware (Zeiss). Individual channels were collected sequentially.
Laser lines for excitation were 405 nm, 488 nm, and 561 nm.
Emissions were collected between 440 and 480, 505 and 550, and
Table 1. Antibodies used in the immunohistochemical study
Target Antibody species Antibody/Source Dilution Secondary antibody
Melanopsin Rabbit polyclonal UF006, Advanced Targeting Systems 1:2500 Donkey anti-rabbit Alexa 488
UVS opsin Goat polyclonal sc-14363, Santa Cruz Biotech 1:1000 Donkey anti-goat Alexa 488
MWS opsin Rabbit polyclonal JH492, Gift J. Nathans 1:1000 Donkey anti-rabbit Alexa 568
Rhodopsin Mouse monoclonal ID4, Gift Ji. Cowing 1:5000 Donkey anti-mouse Alexa 488
TH Chicken polyclonal ab76442, Abcam 1:1000 Donkey anti-chicken Alexa 488
PKC alpha Rabbit polyclonal ab32376, Abcam 1:1000 Donkey anti-rabbit Alexa 568
Calbindin Rabbit polyclonal ab11426, Abcam 1:1000 Donkey anti-rabbit Alexa 568
Brn3a Goat polyclonal sc-31985, Santa Cruz Biotech 1:1000 Donkey anti-goat Alexa 488
Cone arrestin Rabbit polyclonal ab15282, Millipore 1:1000 Donkey anti-rabbit Alexa 568
MW8 Mouse monoclonal Developmental Studies Hybridoma Bank 1:1000 Donkey anti-mouse Alexa 488
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580 and 625 nm for blue, green and red fluorescence respec-
tively. For all images, global enhancement of brightness and
contrast was performed using Zen Lite 2011 image analysis soft-
ware (Zeiss). For direct quantitative comparisons (where stated),
all images were acquired and processed under identical
conditions.
Statistics
Statistical analyses were performed using Statistica 19.0 soft-
ware (version 12, StatSoft Inc., Tulsa, USA) or Prism 5 (GraphPad
Software Inc., San Diego, USA). Analysis of variance (ANOVA)
with repeated measures was performed to investigate differ-
ences between groups, followed by a post hoc Student Newman
Keuls test when a main effect was found. The results were con-
sidered significant when P< 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
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